

## MAIN ARTICLES

- Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana, Cuba; a Cohort Study. Available at <https://ssrn.com/abstract=4072478> or <http://dx.doi.org/10.2139/ssrn.4072478>.
- Elevated Antibody Titers in Abdala Vaccinees Evaluated by Elecsys® Anti-SARS-Cov-2 S Highly Correlate with UMELISA SARS-Cov-2 ANTI RBD, ACE-2 Binding Inhibition and Viral Neutralization Assays. *Journal of Biotechnology and Biomedicine* 5 (2022):151-157. Available at <https://www.fortunejournals.com/articles/elevated-antibody-titers-in-abdala-vaccinees-evaluated-by-elecsysreg-antisarscov2.pdf>.
- Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). *eClinicalMedicine*. 2022(46):101383. Available at <https://doi.org/10.1016/j.eclinm.2022.101383>.
- An engineered SARS-CoV-2 receptor-binding domain produced in *Pichia pastoris* as a candidate vaccine antigen. *New Biotechnology*. 2022;72:11-21. Available at <https://doi.org/10.1016/j.nbt.2022.08.002>.
- SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala. *Infectious Medicine*. 2022;1:253-261. Available at <https://doi.org/10.1016/j.imj.2022.11.001>.
- Immunogenicity and Safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3 to 18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study). Available at <https://ssrn.com/abstract=4304730>.
- Demonstrating “Abdala” Subunit Vaccine Stability Under Thermal Stress Conditions. *BioProcess J*. 2022;21. Available at <https://doi.org/10.12665/J210A.Izquierdo>.
- Impacto y efectividad de la vacuna Abdala en la provincia Matanzas ante la enfermedad sintomática y la muerte por COVID-19. *Revista Cubana de Salud Pública*. 2022;48(3):e3568. Available at <https://revsaludpublica.sld.cu/index.php/spu/article/download/3568/1846>.
- A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study). Available at [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=4213351](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4213351) or <http://dx.doi.org/10.2139/ssrn.4213351>.

## RELATIVE ARTICLES

- Emergence and evolution of SARS-CoV-2 genetic variants during the Cuban epidemic. *Journal of Clinical Virology Plus*. 2022;2:100-104. Available at <https://doi.org/10.1016/j.jcvp.2022.100104>.
- In-solution buffer-free digestion allows full sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI-MS spectrum. *Analytical and Bioanalytical Chemistry*. 2021; 413:7559-7585. Available at <https://doi.org/10.1007/s00216-021-03721-w>.
- Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials. *Journal of Immunological Methods*. 2022;500:113195. Available at <https://doi.org/10.1016/j.jim.2021.113195>.
- Sequencing of S and N genes of SARS-CoV-2 strains circulating in Cuba during March- September 2020. *Journal of Microbiology and Infectious Diseases*. 2022;12(3):78-88. Available at <https://doi.org/10.5799/jmid.1175386> or <https://dergipark.org.tr/en/download/article-file/2651202>.

## OTHER ARTICLES

- Vaccines and Public Trust: Containing COVID-19 in Cuba. *MEDICC Review*. 2022;24(1). Available at <http://medicreview.org/vaccines-public-trust-containing-covid19-cuba/>.
- Epidemiological Characterization of Patients in the First Eight Weeks Following Detection of SARS-CoV-2 B.1.1.529 (omicron) Variant in Cuba. *MEDICC Review*. 2022;24(3-4):18-23. Available at <https://doi.org/10.37757/mr2022.v24.n3-4.6>.



## ABDALA VACCINE PUBLICATIONS